Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 16,899 shares at $3.48 ($64K) on 2023-06-14, disclosed to the SEC on 2023-06-14.
Open-market purchase of $64k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.34 | 2,149 | $9K | 14.7% |
| 2 | $3.82 | 8,750 | $33K | 52.5% |
| 3 | $3.48 | 6,000 | $21K | 32.8% |
| Total | $3.77 avg | 16,899 | $64K | 100% |
| Filing → |
| AVTX | BUY | 2023-06-09 | $56K | — | Filing → |
| AVTX | BUY | 2023-06-02 | $2K | — | Filing → |
| AVTX | BUY | 2023-05-30 | $7K | — | Filing → |